E-cadherin-Fc chimera protein matrix enhances cancer stem-like properties and induces mesenchymal features in colon cancer cells.


Journal

Cancer science
ISSN: 1349-7006
Titre abrégé: Cancer Sci
Pays: England
ID NLM: 101168776

Informations de publication

Date de publication:
Nov 2019
Historique:
received: 01 05 2019
revised: 23 08 2019
accepted: 30 08 2019
pubmed: 11 9 2019
medline: 13 11 2019
entrez: 11 9 2019
Statut: ppublish

Résumé

Cancer stem cells (CSC) are a subpopulation of tumor cells with properties of high tumorigenicity and drug resistance, which lead to recurrence and poor prognosis. Although a better understanding of CSC is essential for developing cancer therapies, scarcity of the CSC population has hindered such analyses. The aim of the present study was to elucidate whether the E-cadherin-Fc chimera protein (E-cad-Fc) enhances cancer stem-like properties because studies show that soluble E-cadherin stimulates human epithelial growth factor receptor (EGFR) and downstream signaling pathways that are reported to play a crucial role in CSC. For this purpose, we used ornithine decarboxylase (ODC)-degron-transduced (Degron(+)) KM12SM cells as a CSC model that retains relatively low CSC properties. Compared to cultures without E-cad-Fc treatment, we found that E-cad-Fc treatment further suppressed proteasome activity and largely enhanced cancer stem-like properties of ODC-degron-transduced KM12SM cells. These results include increased expression of stem cell markers Lgr5, Bmi-1, SOX9, CD44, and CD44v9, aldehyde dehydrogenase (ALDH), and enhancement of robust spheroid formation, and chemoresistance to 5-fluorouracil (5-FU) and oxaliplatin (L-OHP). These effects could be attributed to activation of the EGFR pathway as identified by extensive phosphorylation of EGFR, ERK, PI3K, AKT, and mTOR. In SW480 cells, E-cad-Fc matrix induced some CSC markers such as CD44v9 and ALDH. We also found that E-cad-Fc matrix showed high efficiency of inducing mesenchymal changes in colon cancer cells. Our data suggest that the E-cad-Fc matrix may enhance CSC properties such as enhancement of chemoresistance and sphere formation.

Identifiants

pubmed: 31505062
doi: 10.1111/cas.14193
pmc: PMC6825015
doi:

Substances chimiques

Antineoplastic Agents 0
BMI1 protein, human 0
CD44 protein, human 0
Hyaluronan Receptors 0
Immunoglobulin Fc Fragments 0
LGR5 protein, human 0
Receptors, G-Protein-Coupled 0
Recombinant Fusion Proteins 0
SOX9 Transcription Factor 0
SOX9 protein, human 0
Oxaliplatin 04ZR38536J
Aldehyde Dehydrogenase EC 1.2.1.3
Polycomb Repressive Complex 1 EC 2.3.2.27
ErbB Receptors EC 2.7.10.1
Proteasome Endopeptidase Complex EC 3.4.25.1
Ornithine Decarboxylase EC 4.1.1.17
Fluorouracil U3P01618RT

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

3520-3532

Subventions

Organisme : Rotary Yoneyama Memorial Foundation
ID : RY036688
Organisme : Kagoshima Shinsangyo Sousei Investment Limited Partnership

Informations de copyright

© 2019 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.

Références

J Natl Cancer Inst. 2014 Feb;106(2):djt373
pubmed: 24491301
Pharmacol Ther. 2016 Apr;160:145-58
pubmed: 26899500
Oncogene. 2014 Jan 9;33(2):225-35
pubmed: 23318419
J Pharm Sci. 2017 Sep;106(9):2642-2649
pubmed: 28322937
Clin Exp Metastasis. 2013 Feb;30(2):189-200
pubmed: 22930170
J Clin Med. 2017 Dec 22;7(1):
pubmed: 29271928
Mol Cancer. 2012 Nov 23;11:87
pubmed: 23174018
Methods Mol Biol. 2012;916:373-85
pubmed: 22914954
Int J Cancer. 2016 Jun 15;138(12):2804-12
pubmed: 26704932
Cancer Med. 2012 Aug;1(1):5-16
pubmed: 23342249
Tumour Biol. 2014 May;35(5):3945-51
pubmed: 24420150
Cancer Metastasis Rev. 2009 Jun;28(1-2):15-33
pubmed: 19169796
Cell. 2008 May 16;133(4):704-15
pubmed: 18485877
FEBS J. 2013 May;280(9):2027-41
pubmed: 23461856
Sci Rep. 2017 Feb 08;7:41838
pubmed: 28176811
Ann Transl Med. 2016 Dec;4(24):519
pubmed: 28149881
Oncol Lett. 2014 Jun;7(6):1936-1940
pubmed: 24932263
Cell Mol Gastroenterol Hepatol. 2017 Mar 14;4(1):55-63
pubmed: 28560289
J Clin Invest. 2009 Jun;119(6):1420-8
pubmed: 19487818
J Appl Genet. 2008;49(2):193-9
pubmed: 18436993
Acta Anat (Basel). 1995;154(1):8-20
pubmed: 8714286
J Cancer. 2017 Sep 30;8(17):3555-3566
pubmed: 29151941
Cancer Res. 2008 May 15;68(10):3645-54
pubmed: 18483246
Mol Cancer Res. 2018 Feb;16(2):286-295
pubmed: 29117943
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Differentiation. 2011 Sep;82(2):89-98
pubmed: 21596473
Oncogene. 2013 Oct 31;32(44):5191-8
pubmed: 23334333
Proc Natl Acad Sci U S A. 2012 Jan 10;109(2):466-71
pubmed: 22190486
Mol Cancer. 2012 Sep 25;11:73
pubmed: 23009336
Kurume Med J. 1998;45(1):121-5
pubmed: 9658761
J Mater Chem B. 2016 Jun 28;4(24):4267-4277
pubmed: 32263408
Hum Reprod. 2003 Jul;18(7):1404-9
pubmed: 12832363
Proc Natl Acad Sci U S A. 2014 Oct 28;111(43):15526-31
pubmed: 25313085
Clin Cancer Res. 2016 Nov 1;22(21):5277-5286
pubmed: 27166395
Oncotarget. 2016 Apr 19;7(16):21527-41
pubmed: 26930717
F1000Res. 2016 Apr 19;5:
pubmed: 27134739
Clin Dev Immunol. 2012;2012:708036
pubmed: 22693526
Clin Cancer Res. 2013 Jun 15;19(12):3234-46
pubmed: 23620408
BMC Dev Biol. 2010 Jun 02;10:60
pubmed: 20525219
PLoS One. 2006 Dec 20;1:e15
pubmed: 17183641
Clin Cancer Res. 2010 Jun 15;16(12):3113-20
pubmed: 20530701
Cell Mol Life Sci. 2012 Oct;69(20):3429-56
pubmed: 22945800
Oncogene. 2008 Nov 24;27(55):6958-69
pubmed: 19029937
Tumour Biol. 2017 Mar;39(3):1010428317692248
pubmed: 28345458
Nat Biotechnol. 2010 Jun;28(6):611-5
pubmed: 20512123
Gastroenterology. 2012 Jul;143(1):234-45.e7
pubmed: 22510202
Gastroenterology. 2015 Nov;149(6):1553-1563.e10
pubmed: 26170137
Cell Stem Cell. 2015 Mar 5;16(3):225-38
pubmed: 25748930
Cancer Res. 2014 Mar 1;74(5):1566-75
pubmed: 24413534
Int J Oncol. 2014 Dec;45(6):2349-54
pubmed: 25269626
J Clin Invest. 2016 May 2;126(5):1745-58
pubmed: 27043282
J Biol Chem. 2012 Feb 3;287(6):3760-8
pubmed: 22170051
J Cell Sci. 2012 Oct 1;125(Pt 19):4417-22
pubmed: 23165231
Int J Oncol. 2014 Dec;45(6):2468-74
pubmed: 25269542
Mol Cancer Ther. 2014 Nov;13(11):2713-26
pubmed: 25249558
Cancer Sci. 2019 Nov;110(11):3520-3532
pubmed: 31505062
Mol Carcinog. 2014 Nov;53(11):893-906
pubmed: 23776059
J Cell Physiol. 2017 Dec;232(12):3261-3272
pubmed: 28079253
J Clin Invest. 2009 Jun;119(6):1417-9
pubmed: 19487817
PLoS One. 2017 Aug 30;12(8):e0184111
pubmed: 28854282
Clin Cancer Res. 2000 Sep;6(9):3719-28
pubmed: 10999766
Neoplasia. 2017 Jul;19(7):549-563
pubmed: 28601643
Am J Physiol Renal Physiol. 2006 May;290(5):F1202-12
pubmed: 16368739
Oncogene. 2016 Jun 2;35(22):2824-33
pubmed: 26387547

Auteurs

Yamin Qian (Y)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.

Xin Wu (X)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.

Yuhki Yokoyama (Y)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.

Daisuke Okuzaki (D)

Genome Information Research Center, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.

Mai Taguchi (M)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.

Haruka Hirose (H)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.

Jiaqi Wang (J)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.

Tsuyoshi Hata (T)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Akira Inoue (A)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Masayuki Hiraki (M)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Masahisa Ohtsuka (M)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Hidekazu Takahashi (H)

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Naotsugu Haraguchi (N)

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Tsunekazu Mizushima (T)

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Shinji Tanaka (S)

Department of Molecular Oncology, Graduate School of Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Masaki Mori (M)

Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Hirofumi Yamamoto (H)

Department of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan.
Department of Gastroenterological Surgery, Graduate School of Medicine, Osaka University, Osaka, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH